Paragraph IV Certification

A Paragraph IV (Para IV) certification is a legal statement by a generic drug applicant (ANDA filer) that a patent listed in the FDA's Orange Book for the reference listed drug (RLD) is either invalid, unenforceable, or will not be infringed by the generic drug as described in the ANDA: THE FOUR CERTIFICATIONS: under 21 U.S.C. § 355(j)(2)(A)(vii), an ANDA applicant must make one of four certifications for each patent listed in the Orange Book for the RLD: PARAGRAPH I: the patent information required has not been filed (the patent is not listed in the Orange Book); PARAGRAPH II: the patent has expired; PARAGRAPH III: the applicant will not seek approval before the expiration date of the patent; PARAGRAPH IV: the patent is invalid, unenforceable, OR will not be infringed by the manufacture, use, or sale of the proposed generic drug; THE KEY LEGAL EFFECT OF PARA IV: under 35 U.S.C. § 271(e)(2)(A), the MERE FILING of an ANDA containing a Para IV certification constitutes an act of patent infringement; this is a statutory act of infringement — no actual manufacture or sale of the generic is required; the purpose is to create a justiciable controversy that allows the patent holder to sue before the generic enters the market; IMMEDIATE RIGHTS: once the Para IV certification is filed, the ANDA filer must provide notice to both the NDA holder AND the patent owner (if different); the notice must meet specific content requirements; the patent holder then has a 45-day window to file a patent infringement suit; THE 30-MONTH AUTOMATIC STAY: if the patent holder files suit within the 45-day window, an automatic 30-month stay of FDA approval is triggered; during this stay, the FDA cannot give final approval to the ANDA (though tentative approval can be granted); the stay runs from the date the patent holder received the Para IV notice (not from the date of suit filing); SIGNIFICANCE: the Para IV process is the central mechanism for pharmaceutical patent litigation under Hatch-Waxman and enables the early resolution of patent disputes before generic market entry.

The Para IV notice letter is a critical document in Hatch-Waxman litigation because its adequacy determines whether the 45-day window and 30-month stay are properly triggered: STATUTORY REQUIREMENTS (21 U.S.C. § 355(j)(2)(B)): the notice must include: (1) a statement that the ANDA has been submitted; (2) the date of ANDA submission; (3) the ANDA number; (4) the established name of the drug for which the ANDA was submitted; (5) the active ingredient(s), strength(s), and dosage form; (6) a detailed statement of factual and legal basis for the opinion that the patent is invalid, unenforceable, OR will not be infringed; THE DETAILED STATEMENT: this is the core of the notice letter; for invalidity arguments: specific patent claims challenged; the prior art being relied upon (§ 102 anticipation — specific references; § 103 obviousness — combination of references; § 112 lack of written description/enablement/indefiniteness); specific analysis of how each cited reference reads on the claims; for non-infringement arguments: each element of each asserted claim; why the generic drug lacks the claimed element (as construed under Markman); specific chemical/structural differences; the detailed statement need not be exhaustive of every possible argument — it just needs to provide sufficient notice to allow the patent holder to evaluate and respond; STRATEGIC CONSIDERATIONS FOR GENERICS: (1) SCOPE OF ARGUMENTS: including every possible argument is not always strategic; arguments not disclosed may still be raised in litigation; the generic applicant does not waive invalidity arguments by not including them in the notice letter; (2) INADVERTENT ADMISSIONS: be careful about claim constructions asserted in the notice letter that might be used against the generic in litigation; (3) TIMING: the 45-day clock runs from receipt of the notice; completing the notice quickly is important to start the clock and get to trial (and thus to launch) earlier; (4) MULTIPLE PATENTS: if multiple patents are listed, each must be addressed; the generic can selectively challenge some patents while certifying Para III for others; STRATEGIC CONSIDERATIONS FOR PATENT HOLDERS: (1) review the notice letter carefully for deficiencies — an inadequate notice letter may not trigger the 45-day window; (2) if the notice is inadequate, the patent holder can challenge its adequacy and restart the clock; (3) the detailed statement in the notice letter is not evidence at trial but reveals the generic applicant's invalidity theories for early discovery planning; (4) the 45-day decision: filing suit triggers the 30-month stay; not filing allows FDA to proceed to approve the ANDA.

The 30-month automatic stay is one of the most powerful tools in pharmaceutical patent law — it automatically delays generic approval while the patent dispute is resolved: TRIGGERING THE STAY: the 30-month stay is triggered when: (1) the ANDA contains a Para IV certification; (2) the ANDA filer provides adequate notice to the NDA holder and patent owner; (3) the patent holder files suit against the ANDA applicant within 45 days of receiving the notice; all three conditions must be satisfied for the stay to arise; if the patent holder does NOT file suit within 45 days, there is no stay and the FDA can approve the ANDA after ANDA filing review is complete; DURATION: the stay runs for 30 months from the date the NDA holder or patent owner received the Para IV notice (not 30 months from filing suit); this is an important distinction — the clock starts at notice receipt, not when suit is filed; EARLY TERMINATION OF THE STAY: the stay terminates before 30 months if: (1) the court enters a final decision finding all of the relevant patents invalid or not infringed; (2) the court enters a final judgment that the ANDA does not infringe any valid claim of the patent; (3) the court enters a court order resolving the dispute; (4) the parties settle and the court enters a consent judgment; NOTE: FDA cannot give FINAL approval while the stay is in effect, but it CAN give tentative approval; tentative approval means: FDA has reviewed the ANDA and would approve it but for the pending 30-month stay; when the stay expires or the case resolves, the ANDA can receive final approval quickly; ONE STAY PER ANDA (MMA 2003): the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 limited the 30-month stay to one per ANDA; before MMA 2003, patent holders could list new patents after ANDA filing and trigger additional 30-month stays (a form of evergreening); after MMA 2003: for any given ANDA, only patents listed at the time of ANDA submission can trigger the 30-month stay; patents listed after ANDA submission can still be enforced but do not get the automatic stay; CALCULATING THE STAY: stay start = date NDA holder or patent owner received Para IV notice; stay end = 30 months from start date OR court decision (whichever comes first); if suit is filed on the 45th day, the stay is retroactive to the notification date.

The 180-day marketing exclusivity available to the first ANDA filer with a Para IV certification is one of the most valuable commercial rights in pharmaceutical law: THE BASIC RULE: under 21 U.S.C. § 355(j)(5)(B)(iv), the first applicant to file an ANDA containing a Para IV certification is eligible for 180 days of marketing exclusivity; during this 180-day period, the FDA cannot approve any other ANDA for the same drug; this exclusivity can be worth hundreds of millions of dollars for major drugs because the first-filer generic faces no generic competition for 6 months; WHEN THE 180-DAY PERIOD BEGINS: the 180-day clock starts on the date of the first commercial marketing of the drug by the first ANDA applicant; the date is triggered by actual commercial marketing — not by FDA approval; this means the first-filer can delay launching and delay the start of the 180-day clock; SAME-DAY FILERS: multiple ANDA applicants who file on the same day (within hours) are all treated as first filers and share the 180-day exclusivity; they can all market simultaneously during the 180 days — the exclusivity is shared, not each getting a separate 180 days; FORFEITURE CONDITIONS (7 UNDER MMA 2003): the first-filer exclusivity can be forfeited if: (1) FAILURE TO MARKET: the first filer fails to market the drug within 75 days of FDA approval or within 30 months of ANDA submission, whichever is earlier; this prevents first-filers from 'parking' the exclusivity to protect the brand; (2) WITHDRAWAL: the first filer withdraws the ANDA or it is considered withdrawn; (3) AMENDMENT: the first filer amends or withdraws the Para IV certification; (4) COURT DECISION AGAINST: a court finally decides the patent is valid and infringed; (5) SETTLEMENT: the ANDA applicant agrees that the patent is valid and infringed; (6) FAILURE TO OBTAIN TENTATIVE APPROVAL: the ANDA has not received tentative approval within 30 months; (7) FIRST FILER AGREEMENT: the first filer enters an agreement with the NDA holder regarding the first filer's exclusivity; THE AUTHORIZED GENERIC PROBLEM: the brand company can manufacture the drug and sell it through a subsidiary at generic prices (an 'authorized generic') during the first filer's 180-day exclusivity period; this was held permissible in Teva Pharmaceuticals v. Crawford (D.C. Cir. 2005); authorized generics dramatically reduce the commercial value of the 180-day exclusivity period.